Chicago's Architect is pushing exchange‑traded futures on GPU and DRAM prices, setting up competition with CME and ICE. The move could make compute costs a tradable asset.

VectorBuilder plans a $50M, 35,000‑sq‑ft R&D lab on Chicago’s South Side, targeting a 2027 opening and expanding the city’s CDMO capacity.

A South Side woman underwent a rare quadruple-organ transplant at UChicago Medicine, receiving both lungs, a kidney and a liver from a single donor in a marathon operation.

A Northwestern study shows montelukast reprograms tumor-supporting immune cells and restores checkpoint-inhibitor response in lab models.

A Lancet‑published consensus has renamed PCOS to PMOS to emphasize hormonal and metabolic causes. Patient groups are split as the three‑year roll‑out begins.

Richard and Gayle Landuyt pledged more than $20 million to rename the University of Illinois entrepreneurship hub and build a Chicago presence to speed startups. The gift will fund leadership, prizes and programming across campus and downtown.

Rush performed the first U.S. thumb joint replacement using the TOUCH CMC 1 prosthesis, a ball‑and‑socket implant designed to restore pinch and speed recovery. The device is beginning to roll out to other U.S. centers.

UChicago professors propose scaling a hands‑on "Tools of Thought" apprenticeship that pairs City Colleges students with Chicago firms to teach the nonroutine skills AI can’t replace.

Interim REMAIN‑1 results suggest a one‑time endoscopic "gut reset" can help maintain weight after stopping GLP‑1 drugs. Topline pivotal data are expected in Q4 2026.

Veil Global sued Norton Rose Fulbright in Cook County, alleging the firm failed to pay a USPTO fee and cost the company licensing value; it seeks at least $100 million.

U of I and IBM renewed the Discovery Accelerator Institute to expand AI, quantum and supercomputing research across Illinois with new projects and student externships.

The Cancer Center at Illinois earned a rare National Cancer Institute designation in April 2026, joining a small group of lab-focused centers. The status could unlock federal infrastructure support and translational partnerships for Illinois.

A Northwestern‑developed drug, elraglusib, doubled one‑year survival in a randomized phase 2 trial for metastatic pancreatic cancer, researchers report. The result sets up a planned phase 3.